In July 2020 Biomapas started an EU funded project of research and development activities by creating an artificial intelligence (AI) tool for pharmacovigilance services.

The main aim of the project – to create a pharmacovigilance system based on artificial intelligence.

Biomapas plans to commercialize the prototype of the technology created during the project in the form of a new pharmacovigilance service which will ensure continuous improvement of drug safety. It is planned that this service will be available on the market within a few months after the completion of the project. The company hopes that the new service will allow it to gain a fairly significant market share in the global market.

Project implementation period: July, 2020 – June, 2023.

The project is co-financed by European Regional Development Fund up to € 1 093 434,66.


In January 2017 Biomapas became active in an EU funded project of strengthening international competitiveness by raising awareness in foreign markets.

Biomapas attended eight International Events/Exhibitions with the aim of introducing the company’s services to key market players for current cooperation as well as to share business development strategy by creating relationships for future collaboration.

EU funding for the project was 50% of costs.

Big Enough To Cover  All Your Needs. Small Enough To Care.

Discover the tailored solutions that Biomapas provides to accelerate your clinical trials and optimize your drug development process.

Clinical Research

Regulatory Affairs


Medical Information